MGMT and glioblastoma: Therefore, the methylation of the MGMT promoter enhances sensitivity to alkylating agents such as temozolomide [173] and prolonged OS and PFS in comparison to unmethylated MGMT glioblastoma [174,175], a rationale for its use as a biomarker in glioblastoma.